A $192M listing funds Apnimed's run-up to a sleep apnea pill

Apnimed raised $192 million in an upsized IPO earmarked for launching its sleep apnea pill, which is not yet on the market.

Apnimed has raised $192 million in an upsized initial public offering, with the proceeds earmarked for the launch of its sleep apnea pill. The drug is still pre-launch; this is the money for the run-up to it.

An oral treatment would move sleep apnea out of the category of conditions managed with bedside equipment and into the category of an ordinary prescription — cheaper to distribute, easier to carry, and reachable anywhere a pharmacy is. That is a change in delivery rather than a new capability, but delivery is usually what decides how many people actually get treated for a common condition. We could not read the full article, and the clinical detail, pricing and launch timing sit with the company.

Source: Fierce Biotech